Follicular Lymphoma
342
73
111
110
Key Insights
Highlights
Success Rate
65% trial completion
Published Results
80 trials with published results (23%)
Research Maturity
110 completed trials (32% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
17.0%
58 terminated out of 342 trials
65.5%
-21.1% vs benchmark
11%
38 trials in Phase 3/4
73%
80 of 110 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 110 completed trials
Clinical Trials (342)
A Long-term Extension Study of PCI-32765 (Ibrutinib)
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
A Randomised Phase 3 Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Clonal Evolution in Follicular Lymphoma
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Allo HSCT Using RIC and PTCy for Hematological Diseases
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma